ProMIS Neurosciences Reports Q3 2026 Financial Results and PMN310 Clinical Progress
ProMIS Neurosciences (PMN) reported its third-quarter 2026 financial results, highlighted by a significant increase in cash reserves to $44.1 million following a private placement. The company's net loss for the quarter narrowed to $8.2 million ($0.89 per share) compared to $11.6 million ($5.93 per share) in the prior year period, aided by a 32% reduction in research and development expenses. On the clinical front, the company provided interim updates for its lead Alzheimer’s candidate, PMN310, via the Phase 1b PRECISE AD study. Key biomarker data showed a 15% reduction in plasma p-tau217 and a 13.3% decrease in CSF MTBR-tau243. Management expects to release unblinded 12-month topline data regarding safety, biomarkers, and clinical efficacy in the first quarter of 2027.
Tickers: $PMN
Topics: Alzheimer's research biomarkers cash position clinical trial data earnings report